Rezolute Inc.
(RZLT)
undefined
undefined%
At close: undefined
5.24
0.00%
After-hours Jan 03, 2025, 04:00 PM EST
Company Description
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States.
The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.
It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema.
The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017.
Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Rezolute Inc.
| Country | United States |
| IPO Date | Jan 14, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 59 |
| CEO | Nevan Charles Elam J.D. |
Contact Details
Address: 201 Redwood Shores Parkway Redwood City, California United States | |
| Website | https://www.rezolutebio.com |
Stock Details
| Ticker Symbol | RZLT |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001509261 |
| CUSIP Number | 76200L309 |
| ISIN Number | US76200L3096 |
| Employer ID | 27-3440894 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Nevan Charles Elam J.D. | Founder, Chief Executive Officer, Principal Financial Officer & Acting Chairman of the Board |
| Daron G. Evans M.B.A., M.S. | Chief Financial Officer |
| Chris Milks | Vice President & Head of Finance |
| Dr. Brian Kenneth Roberts M.D. | Chief Medical Officer |
| Dr. Davelyn Eaves Hood M.B.A., M.D. | Director and Head of Scientific & Patient Affairs |
| Dr. Raj Agrawal M.D. | Vice President & Head of Ophthalmological Clinical Development |
| Erin O'Boyle | Senior Vice President & Head of Clinical Operations |
| Michael Covarrubias | Senior Vice President & Head of Program & Portfolio Management |
| Michael R. Deperro | Senior Vice President & Head of Corporate Development |
| Robyn Sweinhart | Vice President & Head of Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 30, 2024 | S-8 | Filing |
| Dec 18, 2024 | 4 | Filing |
| Dec 12, 2024 | 4 | Filing |
| Dec 10, 2024 | 8-K | Current Report |
| Dec 10, 2024 | 4 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SCHEDULE 13G/A | [Amend] Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |